Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05789875 · ClinicalTrials.gov registry record · NA

Youth Ending the HIV Epidemic

A NA study of HIV/AIDS and Young Adults, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
28
Enrollment target
1
Study location

NCT05789875: Completed NA study of HIV/AIDS and Young Adults, sponsored by University of California, San Francisco.

NCT05789875 is a NA study of HIV/AIDS and Young Adults that has completed, run by University of California, San Francisco. The registered enrollment target is 28 participants, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05789875, a NA study of HIV/AIDS and Young Adults, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

Young adults have a disproportionately high rate of HIV infection, high rates of attrition at all stages of the HIV care continuum, an increased risk of antiretroviral therapy (ART) nonadherence and virologic failure, and a high probability of disease progression and transmission. Tracking and monitoring objective measures of ART adherence in real time is critical to strategies to support adherence and improve clinical outcomes. However, adherence monitoring often relies on self-reported and retrospective data or requires extra effort from providers to understand adherence patterns, making it difficult for providers to accurately determine how to support their patients in real time. In the proposed interventional study, the investigators aim to pilot test an automated directly observed therapy intervention paired with conditional economic incentives to improve ART adherence among youth living with HIV (YLWH) (18-29 years-old) who have an unsuppressed HIV viral load. Aim 1: Conduct a pilot study to assess feasibility and acceptability of the use of automated directly observed therapy with conditional economic incentives (aDOT-CEI) among YLWH (aged 18-29; N= 30) at AIDS Healthcare Foundation (AHF) clinics in California and Florida. Primary outcomes will be feasibility and acceptability, assessed using predefined feasibility metrics and acceptability surveys at three months. Aim 2: Explore experiences of YLWH and staff/providers with the aDOT-CEI intervention and implementation facilitators and barriers. The investigators will conduct in-depth qualitative interviews with a sample of YLWH from Aim 1 and staff/providers purposively selected from participating AHF clinics to explore intervention experiences, potential influences on ART adherence, individual-level and clinic-level barriers and facilitators to intervention implementation, and suggested refinements for a future efficacy trial. The investigators hypothesize that the aDOT-CEI intervention to improve ART adh

Primary Outcome

Rate of Participant Retention will be calculated as the percent of those who were retained in the study and completed the final survey.

Interventions

  • OTHER aDOT-CEI

Study Locations (1)

California

  • UCSF Center for AIDS Prevention Studies - San Francisco

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2023-01-31
Est. Completion 2023-09-08
Phase NA

What the finished NCT05789875 record still lists

NCT05789875 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower).

The record links to 3 conditions, with HIV/AIDS appearing as the primary indexed condition, and to 1 intervention - of which aDOT-CEI is the first listed.

NCT05789875 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05789875 about?

NCT05789875 is a clinical study titled "Youth Ending the HIV Epidemic". Young adults have a disproportionately high rate of HIV infection, high rates of attrition at all stages of the HIV care continuum, an increased risk of antiretroviral therapy (ART) nonadherence and virologic failure, and a high probability of disease progression and transmission. Tracking and monit...

What is the current status of trial NCT05789875?

This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2023-01-31. Estimated completion is 2023-09-08.

What conditions does trial NCT05789875 study?

This clinical trial studies the following conditions: HIV/AIDS, Young Adults, Mobile Health.

What interventions are being tested in trial NCT05789875?

The interventions under investigation include: aDOT-CEI (OTHER).

Who is sponsoring clinical trial NCT05789875?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05789875 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV/AIDS

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05789875's enrollment target sits among peer trials

28 54th of 61 higher than 8 of 61 other HIV/AIDS trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV/AIDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05789875, the US trial registry maintained by the National Library of Medicine. NCT05789875 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.